Cathy Tangen contributes to international study, finding on again-off again prostate cancer treatment has quality of life benefits, but continuous therapy improves overall survival
June 4, 2012
Many men with metastatic, hormone-sensitive prostate cancer live longer on continuous androgen-deprivation therapy (also known as hormone therapy) than on intermittent therapy, according to a 17-year study led by SWOG (formerly Southwest Oncology Group), a cancer research cooperative group.
Trial analysis by PHS investigators reveals supplement hazard in largest-ever prostate cancer prevention study
Nov. 21, 2011
Men who took 400 international units of vitamin E daily had more prostate cancers compared to men who took a placebo, according to an updated review of data from the Selenium and Vitamin E Cancer Prevention Trial (SELECT). The Fred Hutchinson Cancer Research Center Public Health Sciences Division's Phyllis Goodman and Drs. Cathy Tangen and Gary Goodman (whose primary appointment is at the Swedish Cancer Institute) analyzed the data for this study.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.